Supply Chain

After a months-long review process that sparked a heated internal debate, the Food and Drug Administration Monday approved eteplirsen as the first treatment for Duchenne muscular dystrophy, a rare disease that causes muscle weakness, loss of movement and eventually death,…

Gayle Manchin, mother of Mylan CEO Heather Bresch, allegedly used her role as director of the National Association of State Boards of Education to boost school EpiPen sales, according to USA Today.

The Senate Finance Committee called for an investigation Tuesday into the oversight of Mylan's Medicaid rebates, reported Reuters.

The Food and Drug Administration recently approved Belgium-based Janssen Pharmaceuticals' drug Invokamet XR for first-line use to improve glycemic control in diabetic adults when paired with diet and exercise.

The House Energy and Commerce Committee opened an investigation on the Food and Drug Administration's Office of Criminal Investigations, citing concerns over management issues and employee morale, reported Reuters.

Health plans have long supplied their members with provider directories to assist in finding in-network physicians who are accepting new patients.

An advance copy of her remarks suggests Mylan CEO Heather Bresch plans to defend the price hike for the company's EpiPen before Congress Wednesday. However, Ms. Bresch will acknowledge that the drugmaker could have anticipated consumer distress over the significantly…

The Food and Drug Administration reported a shortage of Bristol-Myers Squibb's cancer drug Etopophos as of Sept. 16.

Ohio police departments are using up their supplies of the anti-overdose drug naloxone at a faster rate than normal to keep up with the state's high numbers of drug overdoses, reports KWQC.

Sarepta Therapeutics' newly approved Duchenne muscular dystrophy drugeteplirsen will cost about $300,000 a year, depending on patient weight, according to STAT.